beta
Trial Radar IA
Lo studio clinico NCT06573593 per Alopecia Areata, Janus Kinase Inhibitors è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study 150 Dati real-world

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT06573593 è uno studio osservazionale per Alopecia Areata, Janus Kinase Inhibitors, attualmente in arruolamento. Avviato il 29 luglio 2024, prevede di arruolare 150 partecipanti. Sotto la guida di Second Affiliated Hospital, School of Medicine, Zhejiang University, dovrebbe concludersi entro il 31 dicembre 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 27 agosto 2024.
Sommario breve
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disea...Mostra di più
Titolo ufficiale

Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study

Patologie
Alopecia AreataJanus Kinase Inhibitors
Altri ID dello studio
  • 20240699
Numero NCT
NCT06573593
Data di inizio (effettiva)
2024-07-29
Ultimo aggiornamento pubblicato
2024-08-27
Data di completamento (stimata)
2026-12-31
Arruolamento (previsto)
150
Tipo di studio
Osservazionale
Stato
In arruolamento
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Tofacitinib treated group
In the real-world settings, patients with AA treated with tofacitinib.
Tofacitinib
In the real-world settings, patients with AA treated with tofacitinib.
Baritinib treated group
In the real-world settings, patients with AA treated with baritinib.
Baricitinib
In the real-world settings, patients with AA treated with Baricitinib.
Ruxolitinib treated group
In the real-world settings, patients with AA treated with ruxolitinib
Ruxolitinib
In the real-world settings, patients with AA treated with Ruxolitinib.
Upadacitinib treated group
In the real-world settings, patients with AA treated with upadacitinib.
Upadacitinib
In the real-world settings, patients with AA treated with Upadacitinib.
Abrocitinib treated group
In the real-world settings, patients with AA treated with abhicitinib.
Abrocitinib
In the real-world settings, patients with AA treated with Abrocitinib.
Ritlecitinib treated group
In the real-world settings, patients with AA treated with ritlecitinib.
Ritlecitinib
In the real-world settings, patients with AA treated with Ritlecitinib.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Mean SALT
Reduction of Severity of Alopecia Tool (SALT) score compared with baseline
at week 24
SALT50
Percentage of patient with more than 50% improvement in SALT score
at week 24
SALT75
Percentage of patient with more than 70% improvement in SALT score
at week 24
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Mean SALT
Reduction of Severity of Alopecia Tool (SALT) score compared with baseline
at week 12, 36, 48, 56
SALT50
Percentage of patient with more than 75% improvement in SALT score
at week 12, 36, 48, 56
SALT75
Percentage of patient with more than 50% improvement in SALT score
at week 12, 36, 48, 56
Safety profile
Any adverse events including infection, hypohepatia, thrombus, gastrointestinal reaction and any other system events.
at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Bambino, Adulto, Adulto anziano
Età minima
2 Years
Sessi idonei
Tutti
  • Patients with alopecia areata between 2 to 18 years old
  • Patients diagnosed with alopecia areata according to AA guideline
  • AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months

  • Patients had previously received hair implants
  • Other alopecia
  • Other diseases may induce alopecia including psoriasis, lichen planus, et al.
  • Unable to estimate SALT score at baseline or at follow-up
  • Patients are participating in other clinical trials
Second Affiliated Hospital, School of Medicine, Zhejiang University logoSecond Affiliated Hospital, School of Medicine, Zhejiang University
Contatti principali dello studio
Contatto: Ru Dai, MD, 15982215914, [email protected]
Contatto: Wu, [email protected]
1 Centri dello studio in 1 paesi

Zhejiang

Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, 310009, China
Ru Dai, Ph.D, Contatto, 86 15982215914, [email protected]
In arruolamento